trastuzumab,pertuzumab
roche
['pertuzumab', 'herceptin', 'breast']
 #asco23 phergain trial. phase 2. late breaking abstract. subset of patients with her2+ early breast cancer treated with herceptin + pertuzumab alone without chemotherapy had &gt; 95% event free survival in short term follow-up. promising but preliminary.
Breast med oncology, chief hem/onc @NYPBrooklyn, prof clinical med @WeillCornell, ethics/spirituality in medicine; long time NY #Jets sufferer; tweets my own